9月17日 - ** 花旗将波士顿科学 BSX.N 股票评级从“买入”下调至“中性”，目标价从57美元下调至50美元
** 该机构表示，这家医疗科技公司今年的经营形势发生急剧转变，其股价受到美国脉冲场消融市场日趋成熟 (link)、竞争加剧、左心耳闭合装置市场停滞、泌尿科业务面临挑战以及网络安全攻击等多重因素的压力 (link)
** 该券商今年迄今已八次下调业绩预期，最近一次是在9月9日，但仍担忧最新一次修订并非终点
** 上周，该公司表示不再预期 (link) 能达到此前发布的第三季度及全年业绩预测
** “多年来，BSX一直是一只稳健地‘超预期并上调’业绩的股票，虽然我们相信它能够渡过难关，但问题解决的时间尚不明确，投资者的耐心已近极限，且我们尚无法把握其复苏路径，”该券商补充道
** 截至上一交易日收盘，BSX今年累计跌幅达54%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.